Alnylam Pharmaceuticals
ALNY
#585
Rank
S$45.20 B
Marketcap
$352.10
Share price
1.90%
Change (1 day)
39.59%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of June 2024 : S$1.69 B

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is S$1.69 B. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2023-12-31S$1.72 B-2.59%
2022-12-31S$1.76 B31.56%
2021-12-31S$1.34 B95.25%
2020-12-31S$0.68 B68.65%
2019-12-31S$0.40 B899.7%
2018-12-31S$40.86 M1.85%
2017-12-31S$40.12 M-81.52%
2016-12-31S$0.21 B
2007-12-31S$9.77 M-30.25%
2006-12-31S$14 M13.78%
2005-12-31S$12.31 M15.96%
2004-12-31S$10.61 M235.61%
2003-12-31S$3.16 M

Total debt for similar companies or competitors

Company Total debt differencediff. Country
S$0.15 B-90.94%๐Ÿ‡บ๐Ÿ‡ธ USA
S$3.52 B 107.38%๐Ÿ‡บ๐Ÿ‡ธ USA
S$1.78 B 5.08%๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.35 B-79.33%๐Ÿ‡บ๐Ÿ‡ธ USA
S$1.83 M-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
S$37.75 B 2,123.44%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
S$33.16 B 1,852.96%๐Ÿ‡ซ๐Ÿ‡ท France
S$24.64 B 1,351.41%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel